SciBase: Interim report
Comunicato Precedente
Comunicato Successivo
The second quarter in figures
The first half-year in figures
Important events during the quarter
Important events after the end of the period
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August19, 2025.
This interim report has not been subject to review by the Company's auditors
This report, together with previously published interim reports, can be found in its entirety on the company's website: http://investors.scibase.se/en/reports-and-presentations
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase:
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/interim-report,c4219521
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/scibase-interim-report-302533194.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




